Please login to the form below

Not currently logged in
Email:
Password:

Pfizer agrees MoU with Chinese firm

Pfizer has signed a memorandum of understanding (MoU) with Shanghai Pharmaceuticals Co

Pfizer has signed a memorandum of understanding (MoU) with Shanghai Pharmaceuticals Co that includes selling and distributing an unnamed Pfizer product in China. 

The companies plan to explore future co-operation opportunities, including further distribution and commercialisation, research and development activities, manufacturing and equity investment opportunities. 

The companies also expect to strengthen their existing co-operation for the promotion of Pfizer's Prevenar (7-valent) a pneumococcal conjugate vaccine, approved for use in China for active immunisation of infants and toddlers for the prevention of invasive diseases caused by the bacterium Streptococcus pneumonia. 

David Simmons, president and general manager, emerging markets and established products of Pfizer, said: "Our intent to explore a range of business opportunities with Shanghai Pharmaceutical is an example of our commitment to expand our presence in China in collaboration with the local industry." 

Shanghai Pharmaceutical has been one of Pfizer's major partners in China for years and is its largest distribution customer in the market.

21st April 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics